SecBot SecBot
SECBOTREPLAY Home › Report › EWTX

EWTX · Edgewise Therapeutics completed the sale of its sevasemten muscular…

Edgewise Therapeutics, Inc. · 8-K filed Jul 13, 2026 at 08:37 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 13, 2026 at 08:37 ET

Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestones, for total potential consideration of up to $2.65 billion. The transaction transforms Edgewise into a cardiovascular-focused company and is expected to fully fund EDG-7500 development through potential approval. The closing removes deal risk and provides a strong cash runway.

  • Edgewise received $1.55 billion in upfront cash from Servier for the sevasemten program.
  • Up to $1.1 billion in additional regulatory and commercial milestones, for aggregate potential consideration of up to $2.65 billion.
  • Transaction closed on July 10, 2026, as previously announced on June 1, 2026.
  • Company is now a cardiovascular-focused biopharma with pipeline including EDG-7500, EDG-15400, and EDG-003.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access